Medtronic upgraded by Needham with a new price target
$MDT
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
Needham upgraded Medtronic from Hold to Buy and set a new price target of $121.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/4/2026 | $90.00 | Neutral → Buy | BTIG Research |
| 5/21/2026 | $84.00 | Neutral | Goldman |
| 2/13/2026 | $116.00 | Overweight | Barclays |
| 2/9/2026 | $121.00 | Hold → Buy | Needham |
| 2/3/2026 | $117.00 | Buy | Citigroup |
| 1/30/2026 | $114.00 | Overweight | Wells Fargo |
| 1/6/2026 | Mkt Perform → Outperform | William Blair | |
| 11/19/2025 | $111.00 | Sell → Neutral | Goldman |
4 - Medtronic plc (0001613103) (Issuer)
IRANNOTICE - Medtronic plc (0001613103) (Filer)
10-K - Medtronic plc (0001613103) (Filer)
8-K - Medtronic plc (0001613103) (Filer)
Advanced compute power, built on NVIDIA infrastructure, enables real-time decision support during the procedureFDA-cleared Instrument Exit Point (IEP), the first real-time AI application for robotic procedures from Medtronic, advances a precise, predictable, and personalized future for surgeryGALWAY, Ireland, July 21, 2026 /PRNewswire/ -- Medtronic (NYSE:MDT), a global leader in healthcare technology, is presenting an early look at its next-generation compute platform for the operating room. Touch Surgery™ Aide — an AI-native surgical computing platform that powers the Touch Surgery™ ecosystem — enables real-time artificial intelligence during procedures. Touch Surgery™ Aide will be shared a
GALWAY, Ireland, July 20, 2026 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that it will report financial results on Tuesday, September 1, 2026, for its first quarter of fiscal year 2027, which ends on Friday, July 31, 2026.A news release containing summary financial information will be issued at 5:45 a.m. Central Time (CT) and will be available at https://news.medtronic.com.A video webcast to discuss results will begin at 6:45 a.m. CT and can be accessed at https://investorrelations.medtronic.com.Within 24 hours of the video webcast, a replay and transcript of the prepared remarks will be available by clicking on the Events link at http
Acquisition adds category-defining SPRINT® PNS technology to Medtronic's pain therapy portfolio—the broadest in the industry.¹GALWAY, Ireland, July 16, 2026 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it has completed its acquisition of SPR Therapeutics, Inc. (SPR), a privately held medical technology company and recognized leader in short-term, percutaneous peripheral nerve stimulation (PNS) therapies for chronic and acute pain management. The acquisition is valued at $650 million, consisting of an upfront cash payment.Chronic pain affects nearly 50 million U.S. adults2, and for some, it can significantly impact their mobility, sleep q
4 - Medtronic plc (0001613103) (Issuer)
3 - Medtronic plc (0001613103) (Issuer)
4 - Medtronic plc (0001613103) (Issuer)
BTIG Research upgraded Medtronic from Neutral to Buy and set a new price target of $90.00
Goldman resumed coverage of Medtronic with a rating of Neutral and set a new price target of $84.00
Barclays resumed coverage of Medtronic with a rating of Overweight and set a new price target of $116.00
GALWAY, Ireland, July 8, 2025 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced the appointment of Chad Spooner as chief financial officer (CFO) of MiniMed, in advance of its intended separation into a standalone, public company. Effective July 14, 2025, Chad will be responsible for overseeing the Finance function for Medtronic Diabetes and supporting initiatives aimed at accelerating profitable growth and delivering shareholder value as it prepares to become fully independent. Chad brings over 25 years of financial leadership experience across healthcare, consumer, and industrial sectors. Most recently, he served as CFO at BIC (BB:PA), a pu
GALWAY, Ireland, June 23, 2025 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that its Board of Directors appointed Dr. Joon Lee, CEO at Emory Healthcare, Inc., to the Board as an independent director, effective June 18, 2025. Dr. Lee will serve on the Science and Technology Committee and Compensation and Talent Committee of the Board. "We are thrilled to welcome Dr. Lee, a highly respected interventional cardiologist and healthcare executive, to Medtronic's Board of Directors," said Geoff Martha, chairman and chief executive officer. "Dr. Lee brings deep expertise as a clinical researcher, academic leader, and physician executive with dec
NEW HOPE, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company")), a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its full year 2024 financial results and provided a fourth quarter business update. "We remain highly focused on execution of the BACKBEAT global pivotal study, which we believe has the potential to deliver landmark results that can establish AVIM therapy as a new standard of care for the treatment of uncontrolled hypertension in patients already indicated for a pacemaker. We also believe it can lay the foundation for
GALWAY, Ireland, March 5, 2026 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE:MDT) on Thursday, March 5, 2026, approved the company's cash dividend for the fourth quarter of fiscal year 2026 of $0.71 per ordinary share. This quarterly declaration is consistent with the dividend increase announcement made by the company in May 2025. Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 48 consecutive years. The dividend is payable on April 17, 2026, to shareholders of record at the close of business on March 27, 2026.About MedtronicBold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquarte
Cardiovascular portfolio up 11% year-over-year; Cardiac Ablation Solutions grew 80% on strength of pulsed field ablation portfolioGALWAY, Ireland, Feb. 17, 2026 /CNW/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced financial results for its third quarter (Q3) of fiscal year 2026 (FY26), which ended January 23, 2026.Q3 Key HighlightsRevenue of $9.0 billion, increased 8.7% as reported and 6.0% organic, 50 basis points ahead of Q3 guidanceGAAP diluted EPS of $0.89; non-GAAP diluted EPS of $1.36, three cents ahead of Q3 guidance mid-pointCompany reiterates FY26 organic revenue growth and EPS guidanceCardiac Ablation Solutions revenue increased 80%, includin
GALWAY, Ireland, Dec. 4, 2025 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE:MDT) on Thursday, December 4, 2025, approved the company's cash dividend for the third quarter of fiscal year 2026 of $0.71 per ordinary share. This quarterly declaration is consistent with the dividend increase announcement made by the company in May 2025. Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 48 consecutive years. The dividend is payable on January 16, 2026, to shareholders of record at the close of business on December 26, 2025. About MedtronicBold thinking. Bolder actions. We are Medtronic. Medtronic plc, hea
SC 13G/A - Medtronic plc (0001613103) (Subject)
SC 13G/A - Medtronic plc (0001613103) (Subject)
SC 13G/A - Medtronic plc (0001613103) (Subject)